Endologix (NASDAQ: ELGX) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Endologix to similar companies based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, dividends and risk.
This table compares Endologix and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Endologix has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Endologix’s rivals have a beta of 0.79, suggesting that their average stock price is 22% less volatile than the S&P 500.
Valuation and Earnings
This table compares Endologix and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Endologix||$192.93 million||-$154.67 million||-4.94|
|Endologix Competitors||$1.67 billion||$207.76 million||51.80|
Endologix’s rivals have higher revenue and earnings than Endologix. Endologix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings for Endologix and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endologix currently has a consensus price target of $5.36, suggesting a potential upside of 16.71%. As a group, “Medical Devices & Implants” companies have a potential upside of 40.63%. Given Endologix’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Endologix has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
54.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 4.1% of Endologix shares are held by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Endologix rivals beat Endologix on 10 of the 13 factors compared.
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.